Skip to main content

Table 3 Selected clinical trials assessing PARP inhibitors in triple negative breast cancer

From: Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications

Trial Target Treatment vs. control arm Phase Setting Key results
(Treatment vs. control)
PARP inhibitors targeting germline BRCA-mutated tumors
OlympiAD [132] PARP inhibition
(olaparib)
Olaparib
vs. Chemotherapy (physician’s choice)
III Metastatic
Her2-
PFS 7.0 vs. 4.2 months
HR 0.58 (95%CI 0.43–0.80; P < 0.001)
EMBRACA [133] PARP inhibition
(talazoparib)
Talazoparib
vs
Chemotherapy (physician’s choice)
III Metastatic
Her2-
PFS 8.6 vs. 5.6 months
HR 0.54 (95%CI 0.41–0.71; P < 0.001)
BROCADE 3 [134, 135] PARP inhibition
(veliparib)
Veliparib + chemotherapy
vs
Placebo + chemotherapy
III Metastatic
Her2-
PFS 14.5 months vs. 12.6 months
HR 0.71 (95%CI 0.57–0.88; P = 0.002)
For veliparib vs. placebo as a maintenance monotherapy
PFS 25.7 months vs. 14.6 months
HR 0.49 (95%CI 0.34–0.73; P < 0.001)
OlympiA [136] PARP inhibition
(olaparib)
Olaparib vs. Placebo III Adjuvant
Her2-
3-year iDFS 85.9% vs. 77.1%
HR 0.58 (95%CI 0.41–0.82; P < 0.001)
PARP inhibitors targets beyond germline BRCA-mutated tumors
TBCRC048 [137] PARP inhibition
(olaparib)
Olaparib II Metastatic breast cancer
Cohort (1): germline mutations in non-BRCA1/2
homologous repair-related genes
Cohort (2): somatic mutations in non-BRCA1/2
homologous repair-related genes or somatic BRCA1/2
Objective response rate 82% among germline PALB2
Objective response rate 50% among somatic BRCA1/2 (primary endpoint met if objective response rate > 20%)
SWOG S1416 [138] PARP inhibition
(veliparib)
Veliparib + cisplatin vs. Placebo + cisplatin II Metastatic TNBC PFS 5.7 months vs. 4.3 months HR 0.58, P = 0.02 among high HRD tumors
  1. Abbreviations: PFS progression free survival, iDFS invasive disease-free survival, HR hazard ratio, CI confidence interval, TNBC triple negative breast cancer